Press Releases

Emergent BioSolutions Completes Spin-Off of Aptevo Therapeutics

...

Read More

Emergent BioSolutions to Release Second Quarter 2016 Financial Results and Conduct a Conference Call on August 4, 2016

...

Read More

Emergent BioSolutions Announces Commencement of When Issued Trading of Aptevo Common Stock

...

Read More

Emergent BioSolutions Announces Effectiveness of Aptevo Therapeutics Form 10 Registration Statement

...

Read More

Emergent BioSolutions to Implement Stock Repurchase Program for Up to $50 Million of Its Common Stock

...

Read More

Emergent BioSolutions’ Board of Directors Approves Spin-Off of Aptevo Therapeutics and Sets Record and Dividend Distribution Dates and Distribution Ratio

...

Read More

Emergent BioSolutions Receives BARDA Task Order Valued at Up to $21.9 Million to Develop and Manufacture a Zika Vaccine

...

Read More

U.S. Government Issues Solicitation Notices Providing Path to Achieve a Stockpile to Protect 25 Million People Through Procurement of Up to 56.4 Million Doses of Anthrax Vaccines

...

Read More

FDA Completes Pre-Approval Inspection of Emergent BioSolutions’ Large-Scale Manufacturing Facility for BioThrax

...

Read More

FDA Accepts Emergent BioSolutions’ Supplemental Biologics License Application for Large-Scale Manufacturing of BioThrax in Building 55

...

Read More

Emergent BioSolutions Receives FDA Orphan Drug Status for BioThrax for Post-Exposure Prophylaxis of Anthrax Disease

...

Read More

Emergent BioSolutions Reports First Quarter 2016 Financial Results

...

Read More